Avantor, Inc.
AVTR Healthcare Medical Instruments & Supplies
Avantor, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6.6 billion, down 3.41% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS fell 33.3%, free cash flow grew 12.7% and total debt fell 12.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow AVTR
Avantor, Inc. (AVTR) EV/Sales
As of 16 October 2026, Avantor, Inc. (AVTR) trades at a EV/Sales of 2.2×. Over the past ten years it has ranged from 0.0× (June 2019) to 4.4× (September 2021); the current reading is higher than 32% of that period. That is below the Medical Instruments & Supplies industry median of 2.9× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 1.7× | (34.95%) |
| FY2024 | 2.7× | (9.89%) |
| FY2023 | 3.0× | 13.02% |
| FY2022 | 2.6× | (38.73%) |
| FY2021 | 4.3× | 31.34% |
| FY2020 | 3.3× | 61.15% |
| FY2019 | 2.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 1.5× | 14.00% |
| Mar 2026 | 1.3× | (22.37%) |
| Dec 2025 | 1.7× | (5.72%) |
| Sep 2025 | 1.8× | (5.29%) |
| 28 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| BAX Baxter International Inc. compare | 1.8× |
| BLCO Bausch + Lomb Corporation compare | 2.0× |
| AVTR Avantor, Inc. | 2.2× |
| ALGN Align Technology, Inc. compare | 2.3× |
| ATR AptarGroup, Inc. compare | 2.3× |
| SOLV Solventum Corporation compare | 2.4× |
| COO The Cooper Companies, Inc. compare | 3.2× |
| TFX Teleflex Incorporated compare | 3.6× |
| RGEN Repligen Corporation compare | 12.3× |
| Medical Instruments & Supplies industry median | 2.9× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)